KA
AKRO

Kerrisdale Advisers’s Akero Therapeutics AKRO Stock Holding History

Kerrisdale Advisers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-26,457
Closed -$659K – 67
2020
Q2 		$659K Sell
26,457
-1,643
-6% -$37.5K 0.07% 57
2020
Q1 		$596K Buy
+28,100
New +$603K 0.11% 50

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kerrisdale Advisers's AKRO Position: Q3 2020 in Review

Kerrisdale Advisers sold out of Akero Therapeutics (AKRO) in Q3 2020, closing a stake of 26,457 shares — an estimated $659K sold.

Kerrisdale Advisers first reported a position in AKRO in Q1 2020 and held it in 2 quarters. The position peaked at $659K in Q2 2020. 102 funds tracked by Wall St. Rank hold AKRO as of Q3 2020.

  • Kerrisdale Advisers reported no remaining Akero Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kerrisdale Advisers sold 26,457 Akero Therapeutics shares in Q3 2020, an estimated $659K.
  • Kerrisdale Advisers first reported a position in Akero Therapeutics in Q1 2020 and held it in 2 quarters.
  • Kerrisdale Advisers's Akero Therapeutics position peaked at $659K in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2020.

Based on Kerrisdale Advisers's 13F filing for Q3 2020, filed 16 Nov 2020.